94 related articles for article (PubMed ID: 22025156)
1. Docetaxel/Cyclophosphamide-induced ultraviolet recall dermatitis.
Basile FG; Creamer S
J Clin Oncol; 2011 Dec; 29(34):e840-1. PubMed ID: 22025156
[No Abstract] [Full Text] [Related]
2. Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer.
Swayampakula AK; Alkhouri N; Haut MW; Abraham J
Clin Adv Hematol Oncol; 2007 Dec; 5(12):985-7; discussion 987-8. PubMed ID: 18277960
[No Abstract] [Full Text] [Related]
3. Neutropenic fever rates with adjuvant docetaxel and cyclophosphamide in early breast cancer: audit from regional cancer centre in New South Wales.
Jain A; Linsell J; Briscoe K
Intern Med J; 2014 Dec; 44(12a):1258-9. PubMed ID: 25442763
[No Abstract] [Full Text] [Related]
4. Adjuvant docetaxel for node-positive breast cancer.
Ahluwalia MS; Daw HA
N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16135845
[No Abstract] [Full Text] [Related]
5. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
[No Abstract] [Full Text] [Related]
7. [Medical treatment of early breast cancer: chemotherapy].
Ejlertsen B; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
[TBL] [Abstract][Full Text] [Related]
8. Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.
Puglisi F; Mansutti M; Aprile G; Minisini AM; Di Loreto C; Bazzocchi M; Londero V; Cedolini C; Gentile G; Pizzolitto S; Piga A; Sobrero A
Anticancer Res; 2004; 24(4):2487-93. PubMed ID: 15330203
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the Side Effects of Docetaxel with Cyclophosphamide (TC Therapy)].
Imanishi S; Koyama H; Matsui C
Gan To Kagaku Ryoho; 2015 Jun; 42(6):709-11. PubMed ID: 26199242
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and permanent alopecia.
Tosti A; Palamaras I; Miteva M; Misciali C
J Am Acad Dermatol; 2013 May; 68(5):e151. PubMed ID: 23602186
[No Abstract] [Full Text] [Related]
11. Permanent chemotherapy-induced alopecia: case report and review of the literature.
Tallon B; Blanchard E; Goldberg LJ
J Am Acad Dermatol; 2010 Aug; 63(2):333-6. PubMed ID: 20471136
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant docetaxel for high-risk, node-negative breast cancer.
Martín M; Seguí MA; Antón A; Ruiz A; Ramos M; Adrover E; Aranda I; Rodríguez-Lescure A; Grosse R; Calvo L; Barnadas A; Isla D; Martinez del Prado P; Ruiz Borrego M; Zaluski J; Arcusa A; Muñoz M; López Vega JM; Mel JR; Munarriz B; Llorca C; Jara C; Alba E; Florián J; Li J; López García-Asenjo JA; Sáez A; Rios MJ; Almenar S; Peiró G; Lluch A;
N Engl J Med; 2010 Dec; 363(23):2200-10. PubMed ID: 21121833
[TBL] [Abstract][Full Text] [Related]
14. [Clinical utility of adjuvant TC regimen].
Aogi K
Nihon Rinsho; 2012 Sep; 70 Suppl 7():597-600. PubMed ID: 23350470
[No Abstract] [Full Text] [Related]
15. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.
Bicakli DH; Varol U; Degirmenci M; Tunali D; Cakar B; Durusoy R; Karaca B; Ali Sanli U; Uslu R
J Oncol Pharm Pract; 2016 Feb; 22(1):46-53. PubMed ID: 25233884
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant docetaxel for node-positive breast cancer.
Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla JP; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C;
N Engl J Med; 2005 Jun; 352(22):2302-13. PubMed ID: 15930421
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
19. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]